VDR and type 2 diabetes mellitus: The Antiproteinuric Effect of Selective Vitamin d Receptor Activation by Paricalcitol in Type 2 Diabetes Patients on Low or High Sodium Diet and Stable Ras Inhibitor Therapy (PROCEED) trial [23] is exploring the antialbuminuric effect of 2 μg/24 h paricalcitol or placebo for four months on top of RAS blockade in patients with T2DM and UACR >300 mg/24 h who have low or high salt intakes, in order to clarify the interaction between salt intake and VDR activators.